Boehringer Ingelheim Forms Over $2 Billion RNA Therapy Collaboration with Ribo
January 3, 2024
Boehringer Ingelheim is partnering with Chinese biotech Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals in a deal worth over $2 billion to develop RNA treatments for metabolic-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH). This collaboration focuses on utilizing Ribo’s RIBO-GalSTAR platform, which targets disease-causing genes in liver cells. Boehringer, experienced in cardiovascular, renal, and metabolic diseases, hasn’t disclosed specific targets or detailed financials but is committed to upfront payment, clinical, regulatory, commercial milestones, and royalties. This deal follows Boehringer’s previous partnerships with Dicerna Pharmaceuticals and MiNA Therapeutics for MASH treatment.
To read more, click here.
[Source: Fierce Biotech, January 3rd, 2023]
